Cargando…

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study

Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is an ultra‐rare, blood‐clotting disorder. Management historically relies on plasma exchange and immunosuppression; however, a 10%–20% mortality rate is still observed. Caplacizumab binds to von Willebrand factor and directly inhibits platel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scully, Marie, Dutt, Tina, Lester, Will, Farrington, Emily, Lockwood, Stevie, Perry, Richard, Holmes, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Sickle Cell, Thrombosis, and Benign Haematology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422011/ https://www.ncbi.nlm.nih.gov/pubmed/36051029 http://dx.doi.org/10.1002/jha2.435

Ejemplares similares

Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura
por: Alwan, Ferras, et al.
Publicado: (2021)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
por: Madany, Emaan, et al.
Publicado: (2021)

Erytra blood group analyser and kode technology testing of SARS‐CoV‐2 antibodies among convalescent patients and vaccinated individuals
por: Weinstock, Christof, et al.
Publicado: (2021)

Paroxysmal nocturnal haemoglobinuria, diagnosis and haematological findings, first report from Iran, model for developing countries
por: Jahangirpour, Mohammadali, et al.
Publicado: (2022)

Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset
por: Recht, Michael, et al.
Publicado: (2022)

Facilitating EMA binding test performance using fluorescent beads combined with next‐generation sequencing
por: Glenthøj, Andreas, et al.
Publicado: (2021)

Degradation of red blood cell deformability during cold storage in blood bags
por: Islamzada, Emel, et al.
Publicado: (2021)

Impact of aspirin on bleeding and blood product usage in off‐pump and on‐pump coronary artery bypass graft surgery
por: Little, Christopher, et al.
Publicado: (2022)

Cytopenia associated with copper deficiency
por: Uchino, Kaori, et al.
Publicado: (2021)

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function
por: Tullemans, Bibian M.E., et al.
Publicado: (2021)

A practical and effective strategy in East Asia to prevent anti‐D alloimmunization in patients by C/c phenotyping of serologic RhD‐negative blood donors
por: Ito, Shoichi, et al.
Publicado: (2021)

Homozygous sickle cell disease related mortality in Senegal (2011–2020)
por: Seck, Moussa, et al.
Publicado: (2021)

Routine management, healthcare resource use and patient and carer‐reported outcomes of patients with transfusion‐dependent β‐thalassaemia in the United Kingdom: A mixed methods observational study
por: Shah, Farrukh, et al.
Publicado: (2021)

GDF‐15 is associated with atherosclerosis in adults with transfusion‐dependent beta‐thalassemia
por: Efat, Alaa, et al.
Publicado: (2022)

Cryoprecipitate as an alternative to platelet transfusion in thrombocytopenia
por: Crispin, Philip, et al.
Publicado: (2021)

Complement activation during cardiopulmonary bypass and association with clinical outcomes
por: Kefalogianni, Rengina, et al.
Publicado: (2022)

Fibrin clot characteristics and anticoagulant response in a SARS‐CoV‐2‐infected endothelial model
por: McCafferty, Conor, et al.
Publicado: (2022)

Targeting TRPV1 activity via high‐dose capsaicin in patients with sickle cell disease
por: Glaros, Alexander K., et al.
Publicado: (2022)

NTBI levels in C282Y homozygotes after therapeutic phlebotomy
por: Ryan, Eleanor, et al.
Publicado: (2022)

Management of acute sickle cell priapism in an African (Togo) pediatric department includes conservative measures and intracavernous epinephrine which is safe and efficacious
por: Guedenon, Koffi Mawuse, et al.
Publicado: (2022)

Hematopoietic stem progenitor cells with malignancy‐related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4
por: Katagiri, Takamasa, et al.
Publicado: (2022)

Sickle cell disease patients with COVID‐19 in Guadeloupe: Surprisingly favorable outcomes
por: Bernit, Emmanuelle, et al.
Publicado: (2022)

Haematological and biochemical pathology markers for a predictive model for ITU admission and death from COVID‐19: A retrospective study
por: Rasarathnam, Anuja, et al.
Publicado: (2022)

Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis
por: Manwani, Deepa, et al.
Publicado: (2022)

HemoScreen hematology analyzer compared to Sysmex XN for complete blood count, white blood cell differential, and detection of leukocyte abnormalities
por: Linko‐Parvinen, Anna‐Maria, et al.
Publicado: (2022)

Clinical significance of the increased expression of the WT1 gene in peripheral blood of patients with acquired aplastic anemia
por: Ishiyama, Ken, et al.
Publicado: (2022)

Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism
por: Wilson, Nathaniel R., et al.
Publicado: (2020)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Thrombotic microangiopathies: First report of 294 cases from a single institution experience in Argentina
por: Dos Santos, Célia, et al.
Publicado: (2021)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014)

Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review
por: Hermel, Melody, et al.
Publicado: (2020)

Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura
por: Shin, Jin-Sup, et al.
Publicado: (2022)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura
por: Borogovac, Azra, et al.
Publicado: (2022)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c4jki1s3091n8iq707tqkfn4hg